Financial News · Live Terminal

Northcoast Research Adjusts Pentair Price Target to $106 From $120, Maintains Buy Rating

Pentair (PNR) has an average rating of overweight and mean price target of $103.28, according to analysts polled by FactSet.Price: $81.74, Change: $-1.12, Percent Change: -1.35%

Mizuho Securities Adjusts Price Target on CMS Energy to $78 From $76, Maintains Neutral Rating

CMS Energy (CMS) has an average rating of overweight and mean price target of $83.23, according to analysts polled by FactSet.Price: $75.06, Change: $-0.86, Percent Change: -1.13%

$CMS

Mizuho Securities Adjusts Pentair Price Target to $100 From $122, Maintains Outperform Rating

Pentair (PNR) has an average rating of overweight and mean price target of $103.28, according to analysts polled by FactSet.Price: $81.57, Change: $-1.29, Percent Change: -1.56%

Barclays Adjusts Price Target on CMS Energy to $79 From $81, Maintains Overweight Rating

CMS Energy (CMS) has an average rating of overweight and mean price target of $83.23, according to analysts polled by FactSet.Price: $75.10, Change: $-0.82, Percent Change: -1.08%

$CMS

BMO Capital Adjusts Price Target on CMS Energy to $85 From $84, Maintains Outperform Rating

CMS Energy (CMS) has an average rating of overweight and mean price target of $83.23, according to analysts polled by FactSet.Price: $75.10, Change: $-0.82, Percent Change: -1.08%

$CMS

Seaport Global Securities Adjusts Pentair Price Target to $125 From $130, Maintains Buy Rating

Pentair (PNR) has an average rating of overweight and mean price target of $103.28, according to analysts polled by FactSet.Price: $81.61, Change: $-1.25, Percent Change: -1.51%

BNP Paribas Adjusts Pentair Price Target to $75 From $85, Maintains Underperform Rating

Pentair (PNR) has an average rating of overweight and mean price target of $103.28, according to analysts polled by FactSet.Price: $81.68, Change: $-1.18, Percent Change: -1.42%

TD Cowen Adjusts Pentair Price Target to $75 From $90, Maintains Sell Rating

Pentair (PNR) has an average rating of overweight and mean price target of $103.28, according to analysts polled by FactSet.Price: $81.68, Change: $-1.18, Percent Change: -1.42%

Goldman Sachs Adjusts Pentair PT to $91 From $98, Maintains Neutral Rating

Pentair (PNR) has an average rating of overweight and mean price target of $103.28, according to analysts polled by FactSet.Price: $81.68, Change: $-1.18, Percent Change: -1.42%

Raymond James Adjusts Price Target on Fair Isaac to $1,750 From $2,010, Maintains Outperform Rating

Fair Isaac (FICO) has an average rating of overweight and mean price target of $1,545.50, according to analysts polled by FactSet.Price: $1013.71, Change: $+3.21, Percent Change: +0.32%

Baird Adjusts Price Target on Fair Isaac to $1,549 From $1,547, Maintains Outperform Rating

Fair Isaac (FICO) has an average rating of overweight and mean price target of $1,545.50, according to analysts polled by FactSet.Price: $1014.31, Change: $+3.81, Percent Change: +0.38%

Goldman Sachs Adjusts Price Target on Fair Isaac to $1,543 From $1,528, Maintains Buy Rating

Fair Isaac (FICO) has an average rating of overweight and mean price target of $1,545.50, according to analysts polled by FactSet.Price: $1014.31, Change: $+3.81, Percent Change: +0.38%

Needham Adjusts Price Target on Fair Isaac to $1,650 From $1,975, Maintains Buy Rating

Fair Isaac (FICO) has an average rating of overweight and mean price target of $1,545.50, according to analysts polled by FactSet.Price: $1014.31, Change: $+3.81, Percent Change: +0.38%

Baird Adjusts Price Target on Allegion Public to $165 From $190, Maintains Neutral Rating

Allegion Public (ALLE) has an average rating of overweight and mean price target of $167.36, according to analysts polled by FactSet.Price: $138.98, Change: $+1.12, Percent Change: +0.81%

$ALLE

JPMorgan Adjusts Price Target on Allegion Public to $170 From $180, Maintains Overweight Rating

Allegion Public (ALLE) has an average rating of overweight and mean price target of $167.36, according to analysts polled by FactSet.Price: $138.98, Change: $+1.12, Percent Change: +0.81%

$ALLE

$BIDU$DQ$IBN$INFY$IQ$KRKR$NIO$RDY$SE$SIMO$TLK$UXIN$WIT$ZLAB

Asian Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading

Asian equities traded in the US as American depositary receipts were little changed Wednesday morning, edging 0.03% lower to 2,762.13 on the S&P Asia 50 ADR Index.From North Asia, the gainers were led by semiconductor company Silicon Motion Technology (SIMO) and video streaming service iQIYI (IQ), which climbed 30.4% and 5.9%, respectively. They were followed by used car marketplace Uxin (UXIN) and electric vehicle maker NIO (NIO), which advanced 2.7% and 1.7%, respectively.The decliners from North Asia were led by polysilicon manufacturer Daqo New Energy (DQ) and brand platform 36Kr (KRKR), which fell 9.6% and 6.9%, respectively. They were followed by biopharmaceutical company Zai Lab (ZLAB) and tech company Baidu (BIDU), which were down 5.3% and 3.9%, respectively.From South Asia, the only gainers were IT firm Infosys (INFY) and telecommunications operator Telekomunikasi Indonesia (TLK), which were up 0.6% and 0.2% respectively.The decliners from South Asia were led by tech conglomerate Sea (SE) and pharmaceutical company Dr. Reddy's Laboratories (RDY), which dropped 3.6% and 1.9%, respectively. They were followed by lender ICICI Bank (IBN) and IT firm Wipro (WIT), which lost 1.1% and 1% respectively.Price: $194.15, Change: $+44.97, Percent Change: +30.14%

Dr. Reddy's Laboratories Receives Health Canada Approval for Generic Semaglutide

Dr. Reddy's Laboratories (RDY) said Wednesday it received a Notice of Compliance from Health Canada to market its generic semaglutide injection.The regulatory clearance makes the pharmaceutical manufacturer the first company to obtain approval for the type 2 diabetes treatment in the country, the company said.The authorization covers the 2 mg and 4 mg pen dosages and was granted ahead of the agency's target review date, it said.Shares of the company were down 1.9% in Wednesday trading.Price: $13.77, Change: $-0.26, Percent Change: -1.89%

$RDY

Gilead Sciences Says HIV Combo NDA Gets FDA Priority Review

Gilead Sciences (GILD) said Wednesday the US Food and Drug Administration accepted its new drug application for an investigational once-daily HIV treatment combining bictegravir and lenacapavir, granting priority review with a target action date of Aug. 27.The application is backed by Phase 3 ARTISTRY-1 and ARTISTRY-2 trials, which showed the regimen maintained virological suppression at 48 weeks and was generally well tolerated in adults with HIV, including those switching from multi-tablet regimens or Biktarvy, the company said.The bictegravir 75-milligram and lenacapavir 50-mg combination remains investigational and has not been approved globally, with its safety and efficacy yet to be fully established, the company said.Price: $128.49, Change: $-0.77, Percent Change: -0.60%

$GILD